The health and economic burden of chickenpox and herpes zoster in Belgium

Epidemiology and Infection

Volumn 140, Issue 11, 2012, Pages 2096-2109

  Bilcke, J ^a   Ogunjimi, B ^a,b   Marais, C ^a   De Smet, F ^c,d   Callens, M ^c   Callaert, K ^e   Van Kerschaver, E ^f   Ramet, J ^b   Van Damme, P ^a   Beutels, P ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c National Alliance of Christian Sickness Funds   (Belgium)

^d Environmental and Insurance Medicine ^*  (Belgium)

^e HASSELT UNIVERSITY   (Belgium)

^f Brussels   (Belgium)

Author keywords

Ambulatory; cost; hospitalization; QALY; shingles; varicella

Indexed keywords

ARTICLE; BELGIUM; CHICKENPOX; CONSULTATION; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; ECONOMIC ASPECT; GENERAL PRACTITIONER; HEALTH CARE COST; HEALTH STATUS; HEALTH SURVEY; HERPES ZOSTER; HOSPITAL COST; HOSPITALIZATION; HUMAN; INFECTION RATE; MEDICAL CARE; MEDICAL INFORMATION; MORTALITY; OUTPATIENT CARE; QUALITY OF LIFE; REFERENCE DATABASE; VACCINATION; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; BELGIUM; CHICKENPOX; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; FEMALE; HEALTH CARE COSTS; HEALTH CARE SURVEYS; HEALTH SURVEYS; HERPES ZOSTER; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84869486816     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268811002640     Document Type: Article

References (36)

1. Gershon A, Takahashi M, Seward J. Varicella vaccine. In: Plotkin SA, Orenstein W, Offit P, eds. Vaccines. Pennsylvania: Saunders Company, 2004, pp. 783-823.
2. Hope-Simpson RE. The nature of herpes zoster : a longterm study and a new hypothesis. Proceedings of the Royal Society of Medicine 1965; 58: 9-20.
3. Annemans L, et al. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. Journal of Medical Economics 2010; 13: 537-551.
4. Arvin AM, Koropchak CM, Wittek AE. Immunological evidence of reinfection with varicella-zoster virus.Journal of Infectious Diseases 1983; 148: 200-205. (Pubitemid 13002453)
5. Ogunjimi B, et al. Exploring the impact of exposure to primary varicella in children on varicella-zoster virus immunity of parents. Viral Immunology 2011; 24: 151-157.
6. Vossen MTM, et al. Development of virusspecific CD4(+) T cells on reexposure to varicellazoster virus. Journal of Infectious Diseases 2004; 190: 72-82.
7. Jumaan AO, et al. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. Journal of Infectious Diseases 2005; 191: 2002-2007. (Pubitemid 40800569)
8. Leung J, et al. Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination. Clinical Infectious Diseases 2011; 52: 332-340.
9. Nelson MR, Britt HC, Harrison CM. Evidence of increasing frequency of herpes zoster management in Australian general practice since the introduction of a varicella vaccine. Medical Journal of Australia 2010; 193: 110-113.
10. Yih WK, et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health 2005; 5: 68.
11. Brisson M, et al. Exposure to varicella boosts immunity to herpes-zoster : implications for mass vaccination against chickenpox. Vaccine 2002; 20: 2500-2507. (Pubitemid 34615588)
12. Gershon AA, et al. The protective effect of immunologic boosting against zoster : an analysis in leukemic children who were vaccinated against chickenpox. Journal of Infectious Diseases 1996; 173: 450-453. (Pubitemid 26042448)
13. Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002; 360: 678-682. (Pubitemid 35232336)
14. Bilcke J, et al. Cost-utility of vaccination against chickenpox in children and against herpes zoster in elderly in Belgium. Brussels : Belgian Health Care Knowledge Centre (KCE), 2011.
15. van Hoek AJ, et al. Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England. Vaccine 2011; 29: 2411-2420.
16. Brisson M, Edmunds WJ. Varicella vaccination in England and Wales: cost-utility analysis. Archives of Disease in Childhood 2003; 88: 862-869. (Pubitemid 37194040)
17. Van Casteren V, Bossuyt N. Survey site visit Belgium 15 July 2002. Belgian Sentinel Network of General Practitioners, 2002.
18. Zebra Zone European Research & Service Center. Absenteeism in Belgium 2006 (http://www.securex.eu/ be/website/be/public/0ECE524AE5E24507C125729100 465452-nl/0ECE524AE5E24507C125729100465452- 04-nl.pdf). Accessed 7 December 2011.
19. Vrijens F, et al. Nosocomial infections in Belgium, part 2: impact on mortality and costs. Brussels : Belgian Health Care Knowledge Centre (KCE), 2009.
20. Oxman MN, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine 2005; 352: 2271-2284.
21. Coplan PM, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials : adaptation of the brief pain inventory. Journal of Pain 2004; 5: 344-356. (Pubitemid 39164674)
22. Brisson M, Edmunds WJ. Epidemiology of varicellazoster virus in England and Wales. Journal of Medical Virology 2003; 70 (Suppl. 1) : S9-14.
23. Coplan P, et al. Incidence and hospitalization rates of varicella and herpes zoster before varicella vaccine introduction : a baseline assessment of the shifting epidemiology of varicella disease. Pediatric Infectious Disease Journal 2001; 20: 641-645. (Pubitemid 32652312)
24. Brisson M, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiology and Infection 2001; 127: 305- 314. (Pubitemid 33019542)
25. Smith KJ, Roberts MS. Cost effectiveness of vaccination strategies in adults without a history of chickenpox. American Journal of Medicine 2000; 108: 723-729. (Pubitemid 30621460)
26. Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. Journal of Chronic Diseases 1978; 31: 697-704.
27. Merrett P, et al. Strategies to prevent varicella among newly arrived adult immigrants and refugees : A costeffectiveness analysis. Clinical Infectious Diseases 2007; 44: 1040-1048. (Pubitemid 46580269)
28. Drolet M, et al. A prospective study of the herpes zoster severity of illness. Clinical Journal of Pain 2010; 26: 656-666.
29. Scott FT, et al. The burden of herpes zoster : a prospective population based study. Vaccine 2006; 24: 1308-1314. (Pubitemid 43222038)
30. Opstelten W, et al. Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster : prospective prognostic study. Pain 2007; 132 (Suppl. 1) : S52-9. (Pubitemid 350026201)
31. Drolet M, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life : a prospective study. Canadian Medical Association Journal 2010; 182: 1731-1736.
32. Yawn BP, et al. Herpes zoster recurrences more frequent than previously reported. Mayo Clinic Proceedings 2011; 86: 88-93.
33. Wareham DW, Breuer J. Herpes zoster. British Medical Journal 2007; 334: 1211-1215. (Pubitemid 46954586)
34. Wootton SH, et al. The epidemiology of children hospitalized with herpes zoster in Canada: Immunization Monitoring Program, Active (IMPACT), 1991- 2005. Pediatric Infectious Disease Journal 2008; 27: 112-118.
35. Insinga RP, IItzler RF, Pellissier JM. Acute/subacute herpes zoster : healthcare resource utilisation and costs in a group of US health plans. Pharmacoeconomics 2007; 25: 155-169. (Pubitemid 46175551)
36. White RR, et al. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans. Pharmacoeconomics 2009; 27: 781-792.